First Bank & Trust Sells 173 Shares of Solventum Corporation $SOLV

First Bank & Trust lowered its holdings in Solventum Corporation (NYSE:SOLV) by 4.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,494 shares of the company’s stock after selling 173 shares during the period. First Bank & Trust’s holdings in Solventum were worth $265,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of SOLV. Ameriprise Financial Inc. raised its position in shares of Solventum by 14.8% in the fourth quarter. Ameriprise Financial Inc. now owns 75,874 shares of the company’s stock valued at $5,023,000 after purchasing an additional 9,776 shares during the period. Janus Henderson Group PLC raised its position in shares of Solventum by 2.9% in the fourth quarter. Janus Henderson Group PLC now owns 11,374 shares of the company’s stock valued at $752,000 after purchasing an additional 317 shares during the period. OMERS ADMINISTRATION Corp raised its position in shares of Solventum by 21.7% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 5,842 shares of the company’s stock valued at $386,000 after purchasing an additional 1,040 shares during the period. Man Group plc raised its position in shares of Solventum by 1,032.2% in the fourth quarter. Man Group plc now owns 64,457 shares of the company’s stock valued at $4,258,000 after purchasing an additional 58,764 shares during the period. Finally, Quantinno Capital Management LP raised its position in shares of Solventum by 126.8% in the fourth quarter. Quantinno Capital Management LP now owns 14,575 shares of the company’s stock valued at $963,000 after purchasing an additional 8,149 shares during the period.

Solventum Price Performance

SOLV stock opened at $74.16 on Wednesday. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The stock has a market cap of $12.86 billion, a PE ratio of 34.33, a P/E/G ratio of 2.99 and a beta of 0.53. The firm has a 50 day simple moving average of $73.01 and a two-hundred day simple moving average of $72.47.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter in the previous year, the company earned $1.56 EPS. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Wells Fargo & Company increased their target price on shares of Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Monday. KeyCorp initiated coverage on shares of Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research note on Tuesday, July 1st. Finally, Jefferies Financial Group initiated coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $85.44.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.